Amylyx Pharmaceuticals, Inc.
AMLX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $0 | $1 | $2 | $1 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $1 | $2 | $1 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -77.1% | 1,612.9% | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 51.8% | 93.3% | 86.5% | – |
| EBITDA | -$0 | $0 | -$0 | -$0 |
| % Margin | -333% | 10.5% | -903.5% | – |
| Net Income | -$0 | $0 | -$0 | -$0 |
| % Margin | -345.4% | 12.9% | -892.4% | – |
| EPS Diluted | -4.43 | 0.7 | -2.98 | -1.52 |
| % Growth | -732.9% | 123.5% | -96.1% | – |
| Operating Cash Flow | -$0 | $0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | $0 | -$0 | -$0 |